Product category |
- Intermittent preventive treatment (sulfadoxine-pyrimethamine + amodiaquine)
|
Therapeutic indication |
|
Dosing |
|
Efficacy |
|
Key features |
|
Challenges |
- Drug distribution to healthy subjects mainly via door-to-door campaigns
|
Status |
- 700 million treatments distributed since launch in 2014
- First taste-masked dispersible SPAQ formulation prequalified by WHO
|
Next milestone |
- Extension of the recommendation for children up to their 10th birthday
- Confirmation of potential efficacy and adoption in areas outside of the Sahel region
|
MMV Project Director |
|